US 11,938,217 B2
Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Rahul Dhulaji Bhise, Hyderabad (IN); Ajay Kumar Singh, Princeton, NJ (US); Mahadeo Vasant Mahadik, Hyderabad (IN); Ashish Anilrao Dubewar, Hyderabad (IN); and Molugu Prashanth Reddy, Hyderabad (IN)
Assigned to SLAYBACK PHARMA LLC, Princeton, NJ (US)
Filed by SLAYBACK PHARMA LLC, Princeton, NJ (US)
Filed on Jan. 18, 2023, as Appl. No. 18/098,505.
Application 18/098,505 is a continuation of application No. 17/386,139, filed on Jul. 27, 2021.
Application 17/386,139 is a continuation of application No. 16/170,948, filed on Oct. 25, 2018, granted, now 11,110,054, issued on Sep. 7, 2021.
Claims priority of application No. 201841017552 (IN), filed on May 9, 2018.
Prior Publication US 2023/0149294 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/27 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/40 (2006.01); A61K 47/18 (2017.01)
CPC A61K 9/0019 (2013.01) [A61K 9/08 (2013.01); A61K 31/27 (2013.01); A61K 31/40 (2013.01); A61K 47/183 (2013.01)] 19 Claims
 
1. A stable ready-to-use injectable pharmaceutical composition for reversing effects of non-depolarizing neuromuscular blocking agents in a patient in need thereof, comprising:
(i) about 1 mg/mL of neostigmine or a pharmaceutically acceptable salt, solvate or hydrate thereof,
(ii) about 0.2 mg/mL of glycopyrrolate or a pharmaceutically acceptable salt, solvate or hydrate thereof, and
(iii) a pharmaceutically acceptable liquid vehicle,
wherein the pharmaceutical composition has a pH ranging from 3.0 to 4.0, and
wherein said composition is stable when stored at 40° C. and 75% relative humidity for at least 3 months.